A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9
Novo Nordisk · SGA · Turner Syndrome
Phase 3
Active, not recruiting
47
2026-07
Evidence dashboardStudies since 2012Updated Jul 31, 2026
SomapacitanClinical Trials.
A source-linked view of every Somapacitan study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 21
- Recruiting
- 1
- Completed
- 13
- Terminated
- 0
- Results posted
- 8
- Average enrollment
- 98
- Countries
- 46
- Highest phase
- Phase 3
Largest indexed study
500 participants · NCT06709040 →Developer / research origin
Novo Nordisk
Evidence summary
Activity is not efficacy.
Somapacitan appears in 21 indexed studies: 1 recruiting, 13 completed and 8 with registry results posted. The highest registered development stage in this snapshot is Phase 3. These counts measure registry activity; they do not establish that Somapacitan is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
Novo Nordisk · SGA, Turner Syndrome, Noonan Syndrome, ISS
Phase 3
Active, not recruiting
412
2026-06
A Study to Follow Patients With Adult Growth Hormone Deficiency (AGHD) Treated With Sogroya® for Long Term Safety Information
Novo Nordisk · Adult Growth Hormone Deficiency
Not applicable
Enrolling by invitation
400
2026-06
A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
Novo Nordisk · Short Stature Children Born Small for Gestational Age (SGA)
Phase 2
Active, not recruiting
62
2026-06
Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed
Novo Nordisk · Growth Hormone Deficiency in Children
Not applicable
Enrolling by invitation
200
2026-04
Growth Hormone for the Treatment of Gastroparesis
Mayo Clinic · Gastroparesis
Early Phase 1
Recruiting
10
2026-04
Showing 6 of 8 studies
NCT IDStudyPhase / statusEnrollmentUpdated
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
Novo Nordisk · Growth Hormone Deficiency in Children
Phase 3
Completed
200
2026-05
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
Novo Nordisk · Growth Hormone Disorder · Growth Hormone Deficiency in Children
Phase 2
Completed
76
2026-01
A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.
Novo Nordisk · Growth Hormone Deficiency in Children
Phase 3
Completed
110
2026-01
First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects
Novo Nordisk · Growth Hormone Disorder · Adult Growth Hormone Deficiency
Phase 1
Completed
105
2020-12
A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency
Novo Nordisk · Growth Hormone Disorder · Adult Growth Hormone Deficiency
Phase 1
Completed
35
2020-12
A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency
Novo Nordisk · Growth Hormone Disorder · Growth Hormone Deficiency in Children
Phase 1
Completed
32
2020-12
Showing 6 of 13 studies
No studies in this snapshot.
Full study index
Search Somapacitan trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
21 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 41774755 ↗Jorge AAL, Albanese A, Hojby M, Soltysik K, Edouard T, Grandone A, Tansey M, Mori J. Once-weekly somapacitan in children with Noonan syndrome: randomized controlled phase 3 trial. Eur J Endocrinol. 2026 Mar 4;194(3):393-403. doi: 10.1093/ejendo/lvag041.Linked from NCT05330325PMID 41712606 ↗Abuzzahab J, Dauber A, Hojby M, Soltysik K, Kawai M, Murray PG, Phillip M, Battelino T. Somapacitan in children with idiopathic short stature: a randomized controlled phase 3 study. Eur J Endocrinol. 2026 Feb 4;194(2):242-253. doi: 10.1093/ejendo/lvag027.Linked from NCT05330325PMID 41614610 ↗Juul A, Hojby M, Kawai M, Linglart A, Mori J, Zuckerman-Levin N, Backeljauw P. Somapacitan in children born small for gestational age: 4-year results from phase 2. Eur J Endocrinol. 2026 Feb 4;194(2):157-169. doi: 10.1093/ejendo/lvag017.Linked from NCT03878446PMID 40400262 ↗Miller BS, Blair JC, Rasmussen MH, Frystyk J, Lemminger AK, Maniatis A, Mori J, Bottcher V, Kim HS, Polak M, Horikawa R. Efficacy, safety, and insulin-like growth factor I of weekly somapacitan in children with growth hormone deficiency: 3-year results from REAL4. Eur J Endocrinol. 2025 Apr 30;192(5):651-661. doi: 10.1093/ejendo/lvaf096.Linked from NCT03811535PMID 38368603 ↗Mori J, Ohata Y, Fujisawa Y, Sato Y, Rohrich S, Rasmussen MH, Bang RB, Horikawa R. Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial. Clin Endocrinol (Oxf). 2024 Apr;100(4):389-398. doi: 10.1111/cen.15025. Epub 2024 Feb 18.Linked from NCT03811535PMID 37406251 ↗Miller BS, Blair JC, Rasmussen MH, Maniatis A, Mori J, Bottcher V, Kim HS, Bang RB, Polak M, Horikawa R. Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH. J Clin Endocrinol Metab. 2023 Nov 17;108(12):3090-3099. doi: 10.1210/clinem/dgad394.Linked from NCT03811535PMID 36062966 ↗Miller BS, Blair JC, Rasmussen MH, Maniatis A, Kildemoes RJ, Mori J, Polak M, Bang RB, Bottcher V, Stagi S, Horikawa R. Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial. J Clin Endocrinol Metab. 2022 Nov 25;107(12):3378-3388. doi: 10.1210/clinem/dgac513.Linked from NCT03811535PMID 36995872 ↗Savendahl L, Battelino T, Hojby Rasmussen M, Brod M, Rohrich S, Saenger P, Horikawa R. Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2569-2578. doi: 10.1210/clinem/dgad183.Linked from NCT02616562
Related pages
Keep researching Somapacitan.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.